Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine

por Rothrock, John F, Bloudek, Lisa M, Houle, Timothy T, Andress-Rothrock, Diane, Varon, Sepideh F
Publicado 2014

Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

por Blumenfeld, Andrew M., Patel, Atul T., Turner, Ira M., Mullin, Kathleen B., Manack Adams, Aubrey, Rothrock, John F.
Publicado 2020

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

por Rothrock, John F., Adams, Aubrey Manack, Lipton, Richard B., Silberstein, Stephen D., Jo, Esther, Zhao, Xiang, Blumenfeld, Andrew M.
Publicado 2019

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

por Young, William B., Ivan Lopez, J., Rothrock, John F., Orejudos, Amelia, Manack Adams, Aubrey, Lipton, Richard B., Blumenfeld, Andrew M.
Publicado 2019

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

por Young, William B., Ivan Lopez, J., Rothrock, John F., Orejudos, Amelia, Manack Adams, Aubrey, Lipton, Richard B., Blumenfeld, Andrew M.
Publicado 2019